Business & Development

After the drug called ALBRIOZATM from the American pharmaceutical company Amylyx based in Cambridge, Massachusetts, was approved on June 13 by the Canadian agency Health Canada for the treatment of amyotrophic lateral sclerosis, or ALS, the shares of the pharmaceutical company, reached their highest values since February of this year.

The ALS, also known as Lou Gehrig’s disease, after the baseball player, is a progressive disease that affects nerve cells in the brain and spinal cord causing loss of muscle control. Eventually, it affects motor control of the muscles needed to move, speak, eat, and breathe, leading to a deadly outcome.

In an extension study, ALBRIOZATM showed an increase in the survival of participants who received it for up to 6.5 months, representing a promising alternative for the diagnosed community.

ALBRIOZA or AMX0035 is a drug consumed orally with two active ingredients: phenylbutyrate and taurursodiol, which has been proposed as a reducer of cell death in neurons, decreasing stress on the endoplasmic reticulum and mitochondrial dysfunction. A trial is also being conducted to evaluate its efficacy in treating Alzheimer’s disease (NTC03533257).

Amylix shares stand at $21.87 as of July 7, 2022, up from $13.09 a month ago, before the drug’s approval by Health Canada. Currently, the pharmaceutical company is listed on NASDAQ, and until now, it has only one medication.

Writing by

Sources:

https://www.als.org/ - www.amylyx.com - https://www.nasdaq.com/market-activity/stocks/amlx